-
EGFR Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell Lung Cancer
20 Apr 2024 12:31 GMT
… ; Caelyx, PEGylated liposomal doxorubicin; EGFR, endothelial growth … lung cancer: current treatment and future advances. Transl Lung Cancer Res … with small-cell lung cancer. Clin Lung Cancer. 2003;5(2 … . Non-small-cell lung cancers: a heterogeneous set of …
-
Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024
25 Apr 2024 01:52 GMT
… in Combination with Doxorubicin versus Doxorubicin Alone as First- … Zugazagoitia
Type: Poster
Session: Lung Cancer – Non-Small Cell Local- … with relapsed small cell lung cancer. If positive, LAGOON … treatment of small cell lung cancer (SCLC) when patients …
-
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
04 Apr 2024 11:01 GMT
… non-small cell lung cancers (adenocarcinoma). Despite … been challenging.
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … paclitaxel followed by doxorubicin or epirubicin and …
-
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
28 Mar 2024 11:00 GMT
… patients with metastatic lung cancer, lung cancer continues to … cycles.
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … paclitaxel followed by doxorubicin or epirubicin and …
-
Self-Amplified pH/ROS Dual-Responsive Co-Delivery Nano-System with Chemo-Photodynamic Combination Therapy in Hepatic Carcinoma Treatment
24 Apr 2024 07:54 GMT
… traditional chemotherapeutic drugs like doxorubicin, therapeutic outcomes remain … tumor tissue weight. Doxorubicin (DOX) was employed … , including hepatocellular carcinoma, lung cancer, and pancreatic cancer. … pheophorbide a and doxorubicin in combined treatment …
-
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
21 Mar 2024 11:01 GMT
… non-small cell lung cancer. We sincerely thank … intolerable toxicity.
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … paclitaxel followed by doxorubicin or epirubicin and …
-
Clinical Trials for Oral, Inhaled and Intravenous Drug Delivery System for Lung Cancer and Emerging Nanomedicine-Based Approaches
21 Dec 2023 04:45 GMT
… lung cancers. The two broad histological subtypes of lung cancer are small cell lung cancer … specifically accumulate in lung tumor tissues, improving drug … targeted delivery to lung tumors is a promising … al used inhaled doxorubicin in combination with …
-
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
11 Dec 2023 11:56 GMT
… -small cell lung cancer.”
“Addressing lung cancer reflects the … rank=1.
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … paclitaxel followed by doxorubicin or epirubicin and …
-
Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
07 Dec 2023 12:21 GMT
… lung cancer.”
Merck has an extensive clinical development program in lung cancer … toxicity.
About lung cancer
Lung cancer is the … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … followed by doxorubicin or epirubicin …
-
Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
07 Dec 2023 11:36 GMT
… non-small cell lung cancer (NSCLC) with … docetaxel alone.
About lung cancer
Lung cancer is the leading cause … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … and paclitaxel followed by doxorubicin or epirubicin and …